The debate proposed temporal TFEB modulation but identified no validated biomarkers to guide when TFEB should be enhanced versus inhibited. This represents a critical gap preventing clinical implementation of stage-specific TFEB therapies. Source: Debate session sess_SDA-2026-04-03-gap-debate-20260403-222617-8eb5bdbc (Analysis: SDA-2026-04-03-gap-debate-20260403-222617-8eb5bdbc)
Landscape Summary: What validated biomarkers can determine optimal TFEB activity windows during disease progression? is a 0.9 priority gap in neurodegeneration. It has 0 linked hypotheses with average composite score 0.000. Status: partially_addressed.
Colonna, Sevlever, et al. (TREM2 biology)
What validated biomarkers can determine optimal TFEB activity windows during disease progression? — INVOKE-2 (completed)
No hypotheses linked to this gap yet.
No discussions yet. Be the first to comment.
Create sub-tasks to investigate specific aspects of this gap: